The size of the Point of Care (POC) Diagnostics/Testing Market in Europe was worth USD 6.36 billion in 2019 and estimated to reach USD 10.12 billion by the end of 2024 with a CAGR of 9.72%.
Point-of-care diagnostics allow a speedy, convenient, and cost-efficient way to diagnose diseases at healthcare centres and hospitals. The point-of-care diagnosis is a term collectively used for diagnostic procedures and tests performed on-site. As compared to conventional in-laboratory tests, point-of-care diagnostics have the advantage of speed and convenience without compromising on consistency. The speed factor, especially, is the greatest attribute of point-of-care diagnostics, because faster diagnosis facilitates faster patient management. Point-of-care diagnostics help cut down on the need for sophisticated diagnostic systems for regular tests like blood tests and urine tests.
The Europe point-of-care diagnostics market is at a somewhat developed stage right now, as it is composed of products catering to the needs of various domains. Many advanced points of care diagnostic products are on the verge of being used practically and widely. But, more than innovative and advanced point-of-care devices, there is a great need for inexpensive solutions that can be set up in regions where infectious diseases are highly prevalent. In developing areas, these tests are crucial in counterbalancing the lack of adequate laboratory capacity. It is one of the most promising opportunities that can be grabbed by market players.
The introduction of healthcare information systems such as EHR (e-health records) has substantially increased the penetration rates of these tests, which enables considerable automation of diagnostic competences of any medical facility. Advances in technology and the introduction of cost-effective and high-quality medical solutions aimed at achieving miniaturization and lab automation are expected to serve the point-of-care diagnostics market as a vital driver. Moreover, rising levels of patient awareness are expected to play a crucial role behind the growth because patients, particularly the ones suffering from long-term diseases such as diabetes, are actively participating in the shift relating to the implementation of point-of-care diagnostic practices.
However, there are some certain market restraints that players need to overcome. The effort and coordination required among healthcare centres, researchers, practitioners and manufacturers are the most significant restraining factor for the growth of point-of-care diagnostics market. Also, reluctance from the industry towards changing the existing norms, many products recalls, stringent regulatory framework and unfavourable reimbursement scenario are some of the challenges faced by the point-of-care diagnostics market.
This market research report has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2024.
Regionally, Europe is expected to command a decent share in the overall market in the next five years owing to the presence of premium healthcare infrastructure, established reimbursement framework and high healthcare affordability in this region. Moreover, the presence of high levels of awareness amongst the patient population base as well as the physicians associated with fast disease diagnosis is supportive in the industrial revenue.
Notable companies in the Europe Point of Care (POC) Diagnostics/Testing Market profiled in this report are Abbott Laboratories, Inc., Danaher Corporation, Roche Diagnostics Limited, BioMerieux, Siemens Healthcare, Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., and PTS Diagnostics.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Infectious Diseases
5.1.3 Cardiac Markers
5.1.4 Oncology Markers
5.1.5 OTC Diagnostic Tests
5.1.6 Drugs Of Abuse
5.1.7 Blood Gas Testing
5.1.8 Fertility Testing
5.1.9 Urinalysis
5.1.10 Coagulation
5.1.11 Hematology
5.1.12 Glucose Monitoring
5.1.13 Ambulatory Chemistry
5.1.14 Decentralized Clinical Chemistry
5.1.15 Others
5.1.16 Y-o-Y Growth Analysis, By Product
5.1.17 Market Attractiveness Analysis, By Product
5.1.18 Market Share Analysis, By Product
5.2 End-Users
5.2.1 Introduction
5.2.2 Clinics
5.2.3 Hospitals
5.2.4 Home Healthcare
5.2.5 Ambulatory Care Settings
5.2.6 Laboratories
5.2.7 Others
5.2.8 Y-o-Y Growth Analysis, By End-Users
5.2.9 Market Attractiveness Analysis, By End-Users
5.2.10 Market Share Analysis, By End-Users
5.3 Mode of Delivery
5.3.1 Introduction
5.3.2 OTC
5.3.3 Prescription
5.3.4 Y-o-Y Growth Analysis, By Mode of Delivery
5.3.5 Market Attractiveness Analysis, By Mode of Delivery
5.3.6 Market Share Analysis, By Mode of Delivery
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By End-Users
6.1.3.4 By Mode of Delivery
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By End-Users
6.1.4.4 By Mode of Delivery
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By End-Users
6.1.5.4 By Mode of Delivery
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Danaher Corporation
8.3 Roche Diagnostics
8.4 BioMerieux
8.5 Siemens Healthcare
8.6 Beckman Coulter
8.7 Becton Dickinson and Company
8.8 Johnson & Johnson
8.9 Johnson & Johnson
8.10 PTS Diagnostics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
